Navigation Links
Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
Date:7/28/2010

is a global specialty pharmaceutical and medical device company. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at www.angiotech.com.

About Athersys

Athersys is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing MultiStem(R), a patented, adult-derived "off-the-shelf" stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation and oncology treatment support, ischemic stroke, and inflammatory bowel disease. The Company is also developing a portfolio of other therapeutic programs, including orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE(R)). Athersys has forged several key strategic alliances and collaborations with leading pharmaceutical and biotechnology companies, including Pfizer, Angiotech and Bristol-Myers Squibb, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products.


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Angiotech Pharmaceuticals Announces Conference Call and Webcast
2. Angiotech announces exclusive distribution agreement with B. Braun for Angiotechs proprietary Quill(TM) SRS product line
3. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
4. Angiotech Pharmaceuticals Announces Conference Call and Webcast
5. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
6. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
7. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
8. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
9. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
10. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
11. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up ... many of them wrote: "Take better care of my furry companion." ... designer clothes and top-brand carrying cases to take the little canine ... might also feel compelled to buy some pricey toys at the ...
(Date:1/14/2014)... 2014 In recent years, growing suspicion ... in product development and promotion has led to unprecedented ... fueled by concerns about the insidious impact of commercialization ... spectacular fines to the world’s biggest pharmas for illegal ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental products, has ... arch impressions on its dental blog. , Titled ... serves up a list of tips to help dentists best ... David Little as he crafts a porcelain crown using Kerr’s ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ... data demonstrating the effectiveness of Oncothyreon,s PX-866 in ... were presented earlier today by William D. Hardie, ... Center, Cincinnati, Ohio, at the American Thoracic Society ...
... Cumberland Pharmaceuticals announced today the launch of ... Acetadote (acetylcysteine) Injection , the company,s ... http://www.newscom.com/cgi-bin/prnh/20090518/CL18638 )Available at ... hospital pharmacists and physicians, educators and other healthcare ...
... Biologic,Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic," or ... the People,s,Republic of China ("PRC"), reported strong financial results ... First Quarter 2009 Highlights, -- ... -- Gross profit increased 153.1% to ...
Cached Biology Technology:Oncothyreon's PX-866 is effective in preclinical model of pulmonary fibrosis 2Oncothyreon's PX-866 is effective in preclinical model of pulmonary fibrosis 3Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R) 2Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R) 3China Biologic Products Announces Strong First Quarter 2009 Results 2China Biologic Products Announces Strong First Quarter 2009 Results 3China Biologic Products Announces Strong First Quarter 2009 Results 4China Biologic Products Announces Strong First Quarter 2009 Results 5China Biologic Products Announces Strong First Quarter 2009 Results 6China Biologic Products Announces Strong First Quarter 2009 Results 7China Biologic Products Announces Strong First Quarter 2009 Results 8China Biologic Products Announces Strong First Quarter 2009 Results 9China Biologic Products Announces Strong First Quarter 2009 Results 10China Biologic Products Announces Strong First Quarter 2009 Results 11China Biologic Products Announces Strong First Quarter 2009 Results 12China Biologic Products Announces Strong First Quarter 2009 Results 13China Biologic Products Announces Strong First Quarter 2009 Results 14
(Date:4/17/2014)... need to produce hydrogen sulfide in order to properly ... study from the Center for Craniofacial Molecular Biology at ... Professor Songtao Shi, principal investigator on the project, said ... governs the flow of calcium ions. The essential ions ... osteogenesis, or the creation of new bone tissue, and ...
(Date:4/17/2014)... in German . ... money demanded of him, he can expect his premises to ... fear of the consequences is enough to make restaurant owners ... which lay their eggs in other birds, nests. If the ... take their revenge by destroying the entire nest. Consequently, it ...
(Date:4/17/2014)... in France have hit on a novel method ... the correct and most effective treatment possible., Kidney ... western and developing world. If left untreated, apart ... renal failure and other complications. In many patients ... Clearly a more effective pathological approach to diagnosis ...
Breaking Biology News(10 mins):Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... robust, efficient method of using hydrogen as a fuel source. ... converted to electricity in a fuel cell and because it is ... a gas, it can only be stored in high pressure or ... of hydrogen, "if you got into a wreck, you,d have a ...
... serve remote areas of the world, doctors, nurses and ... relatively inexpensive. Now researchers at the University of ... light-weight, dual-mode microscope that uses holograms instead of lenses. ... published today in the Optical Society,s (OSA) open-access journal ...
... environmental advocates are excited about the prospect of gaining ... like miscanthus or switchgrass rather than corn. ... but one key factor of agriculture has been overlooked: ... energy through bioenergy crops, dependence on water gets ignored, ...
Cached Biology News:Microscope on the go: Cheap, portable, dual-mode microscope uses holograms, not lenses 2Microscope on the go: Cheap, portable, dual-mode microscope uses holograms, not lenses 3Testing the water for bioenergy crops 2
... high quality whole genome sequencing service. Our ... allow even the smallest of laboratories to ... features which set our whole genome sequencing ... strategies, proprietary assembly software, rapid project turnaround ...
Great for biotinylating DNA/RNA probes...
... polyclonal antibody to human XAB2 (amino terminus) ... identified through its interaction with XPA. Immunoprecipitation ... of XAB2 interacts with the transcription-coupled repair-specific ... with RNA polymerase II. Microinjection experiments with ...
... The Bio-Plex maintenance, calibration, ... is a custom 96-well plate ... validation, and calibration procedures using ... This MCV plate is for ...
Biology Products: